Rivoglitazone

Rivoglitazone
Clinical data
ATC code
  • none
Identifiers
  • (RS)-5-{4-[(6-methoxy-1-methyl-1H-benzimidazol-2-yl) methoxy]benzyl}-1,3-thiazolidine-2,4-dione
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H19N3O4S
Molar mass397.45 g·mol−1
3D model (JSmol)
  • CN1C2=C(C=CC(=C2)OC)N=C1COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4
  • InChI=1S/C20H19N3O4S/c1-23-16-10-14(26-2)7-8-15(16)21-18(23)11-27-13-5-3-12(4-6-13)9-17-19(24)22-20(25)28-17/h3-8,10,17H,9,11H2,1-2H3,(H,22,24,25)
  • Key:XMSXOLDPMGMWTH-UHFFFAOYSA-N
  (verify)

Rivoglitazone (INN) is a thiazolidinedione derivative undergoing research for use in the treatment of type 2 diabetes.[1][2]

It is being developed by Daiichi Sankyo.

References

  1. ^ Schimke K, Davis TM (April 2007). "Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes". Current Opinion in Investigational Drugs. 8 (4): 338–344. PMID 17458185.
  2. ^ Kong AP, Yamasaki A, Ozaki R, Saito H, Asami T, Ohwada S, et al. (September 2011). "A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes". Diabetes, Obesity & Metabolism. 13 (9): 806–813. doi:10.1111/j.1463-1326.2011.01411.x. PMID 21492364. S2CID 24974160.
Stub icon

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.